21 Oct ACG 2022 Annual Scientific Meeting, Charlotte, North Carolina

Close this search box.

US study addressing fatty liver disease in children using HepaFat-Scan® technology

29 May, 2015

We are pleased to announce a collaboration with a prestigious children’s hospital in the USA (Children’s Healthcare of Atlanta) who will perform a validation study of HepaFat-Scan® – our non-invasive medical imaging solution that utilises MRI to accurately measure liver fat.

The study will be performed on a paediactic patient population with Non-Alcoholic Fatty Liver Disease (NAFLD). NAFLD is is the leading cause of liver disease in the US and is increasing rapidly worldwide. There are currently no approved pharmaceutical treatments for NAFLD.

General Manager of Resonance Health, Mr Sander Bangma said

“We have worked with Children’s Healthcare of Atlanta for a number of years in the provision of our FerriScan® service to measure liver iron overload. We are delighted that we can now further our collaboration with such a highly-respected institution to provide the HepaFat-Scan service in this study under the direction of Associate Professor Dr. Miriam Vos, a leading clinician and recognized expert in the field of pediatric NAFLD.  HepaFat-Scan can assist clinicians in their diagnosis and treatment of patients, providing them with accurate information at an earlier disease stage. This study intends to show that this information will lead to improved patient outcomes. Collecting data like this may ultimately support inclusion of HepaFat-Scan in clinical guidelines for routine care of NAFLD patients.” 

HepaFat-Scan is also very well suited to be utilised by pharmaceutical companies who are currently racing to develop treatments for NAFLD and associated diseases.

Please see the full ASX announcement here